Neurogene Inc
NGNE
Get informed when a big investor buys or sells
+ FollowMarket Cap$405.33M
Close$
$4.44
82.7% downside
Current Fair Value
82.7% downsideOvervalued by 82.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $405.33 Million |
|---|---|
| Enterprise Value | $301.19 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.24 |
| Beta | 1.96 |
| Outstanding Shares | 22,552,032 |
Return
| Return on Equity | -51.17% |
|---|---|
| Return on Assets | -45.47% |
| Return on Invested Capital | -53.82% |
Valuation & Multiples
| P/E Ratio | -4.66 |
|---|---|
| PEG | -8.22 |
| Price to Sales | - |
| Price to Book Ratio | 2.85 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.51 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-1.42
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-1.33
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1234▼ 10.87% |
|---|---|
| Total Calls | 119,100▼ 27.99% |
| Total Puts | 14,700▼ 61.72% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 76.92%▲ 0.84% |
|---|---|
| Total Invested | $545.51M▲ 59.52% |
| Investors Holding | 117▲ 16.00% |
ESG Score
No data
About Neurogene Inc
66 employeesneoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein d...